Rocket One Q3 10-Q: Going-Concern Warning, Nasdaq Bid-Price Deficiency, $6.0M Cash
RKTO is trading near its 52-week low of $0.316 (1.7% above the low).
Summary
Rocket One disclosed substantial doubt about its ability to continue as a going concern, with $6.0M of cash against a $8.8M nine-month operating burn, alongside a Nasdaq bid-price deficiency and continued ATM dilution.
Key Events · Earnings and Guidance · RKTO
-
Going-Concern Warning Disclosed
Management states $6,016,055 of cash and equivalents at September 30, 2026 is not sufficient to fund operations for at least one year, raising substantial doubt about the company's ability to continue as a going concern.
-
Nasdaq Bid-Price Deficiency
Rocket One received a Nasdaq notice on August 6, 2026 that its stock has traded below $1.00; it has until February 2, 2027 to regain compliance, with a possible second 180-day period, and may use a reverse stock split.
-
Losses Narrow, Burn Persists
Q3 net loss was $2,679,193 ($0.11 per share) versus $4,105,801 ($0.30) a year earlier; nine-month net loss was $9,206,309 against $8,804,413 of operating cash burn.
-
ATM and Placement Fund the Gap
The company sold 5,906,125 ATM shares for $7,750,657 net in the nine months, with $5,257,000 still eligible, and raised $1,611,880 net from 2,857,144 shares at $0.70 plus warrants at $0.85 in April 2026.
Analysis · RKTO · Life Sciences
The filing's own language leaves little room for interpretation: $6.0M of cash will not fund operations for the next twelve months, and a Nasdaq minimum bid-price deficiency notice from August 6, 2026 already sits on the books with a February 2, 2027 cure deadline. Stock sales have been bridging the gap—5,906,125 ATM shares for $7.75M net in the first nine months, plus a $2.0M April placement at $0.70. Losses are narrowing (Q3 net loss $2.68M vs $4.11M a year ago), and the Tracer Drone acquisition finally gives the company a revenue line, though that revenue was $35 for the stub period. The core risk is straightforward: without new capital, the development plan gets curtailed, and the only proven funding channel is more dilution.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RKTO was trading at $0.32 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8M. The 52-week trading range was $0.32 to $2.45. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.